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Background. Little is known about the hepatitis C virus (HCV) epidemic among HIV-infected men who have sex with men 
(HIV+ MSM) in the United States. In this study, we aimed to determine the incidence of primary HCV infection among HIV+ MSM 
in San Diego, California.
Methods. We performed a retrospective cohort analysis of HCV infection among HIV+ MSM attending 2 of the largest HIV 
clinics in San Diego. Incident HCV infection was assessed among HIV+ MSM with a negative anti-HCV test and subsequent HCV 
test between 2000 and 2017, with data censored to 2015. HCV reinfection was assessed among HIV+ MSM successfully treated for 
HCV between 2008 and 2015. Infection/reinfection rates were calculated using person-time methods.
Results. Among 3068 initially HCV-seronegative HIV+ MSM, 178 new infections occurred over 15 796 person-years, giving an 
incidence of 1.13 per 100 person-years (/100py; 95% confidence interval [CI], 0.97–1.31). Incidence was stable from 2000 to 2014 
(0.83/100py; 95% CI, 0.41–1.48), with an increase to 3.01/100py (95% CI, 1.97–4.42) in 2015 (P = .02). Among 43 successfully treated 
patients, 3 were reinfected.
Conclusions. HCV incidence is high among HIV+ MSM in San Diego, with evidence suggesting a recent increase in 2015. 
Strong HCV testing guidelines and active prevention efforts among HIV+ MSM are urgently needed that include rapid diagnosis, 
treatment, and risk reduction.
Keywords. HCV; HIV; incidence; men who have sex with men.
Viral hepatitis was the seventh leading cause of mortality 
worldwide in 2013, with half of these deaths attributable to 
hepatitis C virus (HCV) [1]. In response, the World Health 
Organization (WHO) issued HCV elimination targets, in-
cluding a 90% reduction in HCV incidence by 2030 [2]. 
Among HIV-infected individuals, ~2.3 million (6.2%) are 
coinfected with HCV [3]. These individuals experience ac-
celerated liver disease progression [4] and death [5]; liver-
related death is a leading cause of non-AIDS mortality among 
HIV+ individuals [6, 7].
An epidemic of HCV among HIV-infected men who have 
sex with men (HIV+ MSM) has been documented in urban 
centers in the United States, Europe, and Australia [8–13] that 
is associated with injecting drug use (IDU), but also high-
risk sexual practices and substance use associated with sex 
among those with no history of IDU [8–10, 14]. In Europe, 
dramatic increases in HCV incidence and prevalence among 
HIV+ MSM have been documented [10–13, 15, 16], yet data 
from the Netherlands demonstrating a large reduction in 
HCV incidence among HIV+ MSM concomitant with wide-
spread scale-up of HCV treatment have renewed optimism 
that elimination is possible [17]. Additionally, high rates of 
HCV reinfection have been reported in Europe (5–10 times 
the primary incidence) [18–20]. No published studies have 
reported HCV reinfection rates among HIV+ MSM in the 
United States.
As data on HCV incidence among HIV+ MSM from the 
United States are limited, it is unclear what level of interven-
tion is required to achieve the WHO elimination targets in 
this population. San Diego is the eighth largest US city, with 
~13 200 HIV-diagnosed individuals [21, 22]. To inform clin-
ical and public health strategies, we aimed to determine HCV 
primary incidence among HIV+ MSM in San Diego from 
2000 to 2015.
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METHODS
Study Population
We performed a retrospective cohort study of HIV+ MSM 
identified at 2 of the largest HIV clinics: (1) the University 
of California San Diego Owen Clinic (Owen Clinic) and (2) 
the Veterans Affairs (VA) Hospital in San Diego, California. 
Together, these clinics care for approximately 3400 HIV+ MSM 
(~one-third of all HIV-diagnosed MSM in San Diego) [22]. 
Individuals were included in this study if they were male, HIV-
infected, had ever received care at the Owen Clinic or the VA 
Hospital, and were recorded as having acquired HIV through 
sex between men. Demographic data on age and ethnicity were 
collected. This retrospective HCV cohort study was approved 
by the UCSD Human Research Protection Program and the VA 
Institutional Review Board.
Primary Incidence Calculation
Primary incident HCV infection was assessed among a subset 
of HIV+ MSM with a baseline-negative HCV serology and 
at least 1 more anti-HCV or HCV RNA test during the fol-
low-up period between 2000 and 2017. Results were censored 
at the end of 2015 to reduce the bias arising from the selection 
criteria requiring 2 HCV tests, resulting in lower total person-
years in 2016 and 2017, given a median testing interval (in-
terquartile range [IQR]) of 1.18 (0.59–2.25) years. Follow-up 
time was calculated from the baseline negative anti-HCV date 
to the date of first positive anti-HCV or HCV RNA test, or 
last negative HCV test. The person-time incidence rate was 
calculated as the number of incident infections (any posi-
tive anti-HCV or HCV RNA test) divided by the number of 
person-years (py) of follow-up. Ninety-five percent confi-
dence intervals were calculated using exact Poisson confidence 
limits for the estimated rate. As the period between the last 
negative and first positive test could have been long, a sensi-
tivity analysis was performed calculating the time of infection 
as the midpoint between the last negative and first positive 
HCV test. Univariate analysis was performed to compare the 
incidence rates with the following characteristics (age [≤30, 
31–40, 41–50, >50 years], race [white/black/other], Hispanic 
[yes/no]) using the chi-square test. To evaluate the evolution 
of incidence over the study period, we calculated the annual 
incidence rate and assessed statistical differences in incidence 
over time using a chi-square test for trend in proportions and 
logistic regression.
Reinfection Incidence Calculation
HCV reinfection was assessed among HIV+ MSM who 
attended the Owen Clinic and achieved sustained viral response 
(SVR) with HCV therapy between 2008 and 2014 and had at 
least 1 subsequent HCV RNA measurement before the end of 
2015. No data were available for individuals who attended the 
VA Hospital. Follow-up time was calculated from the date of 
HCV SVR documentation until their first subsequent positive 
HCV RNA or their last HCV test at the Owen Clinic. HCV rein-
fection was defined as having a new detectable HCV viral load 
after documented SVR. Most individuals within our analysis 
were treated with interferon-based regimens; patients who were 
treated in 2014 received interferon-free direct-acting antiviral 
(DAA) medications. HCV SVR was defined as having an un-
detectable HCV viral load after 24 weeks after HCV treatment 
completion with interferon-based regimens and after 12 weeks 
in the interferon-free DAA era. The reinfection rate was calcu-
lated using person-time methods.
RESULTS
Incidence of Primary HCV Infection
A total of 3068 HIV+ MSM (2652 and 416 from the Owen Clinic 
and the VA Hospital, respectively) who initially had a negative 
HCV serology and had at least 1 subsequent HCV test during 
follow-up (median [IQR], 4.2 [1.7–7.9] years of follow-up) were 
included in the analysis of primary incidence. Baseline charac-
teristics for both centers are presented in Supplementary Table 
1. Their median age (IQR) was 39 (31–46) years. Individuals 
who attended the VA Hospital were older (median, 42 years and 
38 years in VA and Owen, respectively; P < .001), less likely to 
be of Hispanic ethnicity (11.6% vs 26.1%; P < .001), and more 
likely to be black (25% vs 9.3%; P < .001).
Overall, from 2000 to 2015, 178 new incident HCV 
infections occurred over 15 796 person-years of follow-up 
(incidence rate,  1.127/100py; 95% confidence interval [CI], 
0.967–1.305) with no difference between sites (1.151/100py; 
95% CI, 0.977–1.347; and 0.987/100py; 95% CI, 0.626–1.481; 
at the Owen Clinic and the VA Hospital, respectively) (Table 
1). Annual incidence trends are presented in Figure 1. From 
2000 to 2014, incidence fluctuated slightly (between 0.49 and 
1.32/100py) but there was no evidence of a changing trend in 
incidence across this time period (P = .92). However, incidence 
was higher in 2015 (3.01/100py; 95% CI, 1.97–4.42) compared 
with 2014 (P = .016) and most previous years (Supplementary 
Table 2)). Indeed, there were 26 incident infections in 2015, 
compared with only 11 in 2014. Individuals were tested 
for HCV a median (IQR) of 2 (1–4) times, with a median 
testing interval (IQR) of 1.18 (0.59–2.24) years. There was a 
trend toward more frequent testing across the entire period 
(Supplementary Table 3), with the median testing interval ex-
ceeding 2 years in the early 2000s and declining to <1 year in 
2014. Annual estimates for HCV incidence from 2000–2015 
were similar if assuming the time of infection to be the mid-
point between the last negative and first positive HCV tests 
(overall incidence, 1.14/100py; 95% CI, 0.979–1.321), and an 
increase in incidence was still observed in 2015 compared 
with previous periods. No differences in incidence were found 
by age, race, or ethnicity (Table 1).
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Incidence of HCV Reinfection
A total of 43 HIV+ MSM achieved SVR after HCV treatment 
between 2008 and 2014 at the Owen Clinic and had at least 1 
subsequent HCV test before the end of 2015. Among these, 
3 became reinfected during 102.5 person-years of follow-up 
(Table 2), leading to an HCV reinfection rate of 2.89/100py 
(95% CI, 0.60–8.44). All 3 reinfected individuals had previously 
been treated with interferon-containing regimens and were in-
itially infected with HCV genotype 1, and all were reinfected 
with HCV genotype 1a. Reinfections occurred at 2.5, 2.7, and 
5.9 years post-SVR. All 3 had at least 1 negative RNA test after 
SVR and before reinfection. Despite behavioral counseling, at 
Table 1. Incident Hepatitis C Virus Infection Among HIV-Positive Men who Have Sex With Men in San Diego Stratified by Baseline Demographics 
No. of Events Person-years Incidence/100py [95% CI] IRR (95% CI) P Value
Overall 178 15 796 1.127 [0.967–1.305] - -
Cohort      
Owen 155 13 466 1.151 [0.977–1.347] 1 -
VA 23 2301 0.987 [0.626–1.481] 0.858 (0.528–1.334) .493
Age      
30 y 41 3382 1.212 [0.870–1.645] 1 -
31–40 y 67 5719 1.171 [0.908–1.488] 0.966 (0.646–1.462) .864
41–50 y 57 4855 1.174 [0.889–1.521] 0.968 (0.637–1.484) .876
>50 y 13 1840 0.707 [0.376–1.208] 0.583 (0.287–1.109) .087
Race      
White 119 9775 1.217 [1.008–1.457] 1 -
Black 21 1816 1.157 [0.716–1.768] 0.950 (0.567–1.519) .829
Other 35 3779 0.926 [0.645–1.288] 0.761 (0.506–1.117) .156
Hispanic      
No 135 11 645 1.159 [0.972–1.372] 1 -
Yes 43 4104 1.048 [0.758–1.411] 0.904 (0.626–1.282) .565
Abbreviations: CI, confidence interval; IDU, injection drug use; IRR, incidence rate ratio; VA, Veteran Affairs Hospital.
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Figure 1. Incidence of primary hepatitis C virus (HCV) infection over calendar time among HIV-infected men who have sex with men in San Diego. Whiskers present 95% 
confidence intervals of the point estimate.
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reinfection diagnosis, 2 reported ongoing IDU, and the third 
reported ongoing unprotected high-risk sexual behaviors 
such as ongoing condomless anal receptive or insertive inter-
course with multiple occasional partners that were engaged 
through the Internet, potentially under the influence of illicit 
nonintravenous stimulant use.
DISCUSSION
This study found the incidence of HCV infection among HIV+ 
MSM in San Diego to be high during 2000–2015, with evidence 
of a recent increase to 3/100 person-years in 2015.
Our study points to the crucial need for frequent HCV 
testing among HIV+ MSM. Additionally, our work highlights 
the importance of developing interventions to prevent HCV 
infection and reinfection among MSM. Unfortunately, data 
on behavioral interventions to prevent HCV infection/reinfec-
tion among MSM are limited. Methamphetamine or chemsex 
interventions may be relevant to this population and should 
be explored [23]. The Swiss HCVree Trial is examining the 
impact of coupled HCV treatment with behavioral risk re-
duction among MSM [24]. More studies on these and other 
interventions are warranted.
Comparison With Other Studies
To our knowledge, we present the largest study of HCV inci-
dence among HIV+ MSM in the United States (>3000 HIV+ 
MSM) and the only estimate of HCV reinfection in this popu-
lation. Our overall incidence estimate of 1.13/100py (95% CI, 
0.97–1.31) is comparable to estimates among 1171 HIV+ MSM 
in Boston from 1997–2009 (1.6/100py; 95% CI, 0.97–2.30) 
[25] and 1184 HIV+ MSM in the multicenter HIV Outpatient 
Study (HOPS) from 2000–2013 (1% overall, 1.3% in 2011–
2013) [26]. However, our primary incidence is higher than 
the 0.4–0.5/100py incidence reported among the 2041 HIV+ 
MSM in the Multicenter AIDS Cohort Study (MACS) cohort 
(Baltimore, Chicago, Pittsburgh, and Los Angeles) [27] and 
among the 1830 HIV-infected male participants of the AIDS 
Clinical Trial Group (ACTG) cohort [28]. These differences 
may be due, in part, to potential differences in testing. In the 
MACS and ACTG studies, the mean testing intervals were 
2.5–2.8  years, whereas ours was 1.18  years, so our shorter 
testing interval could have led to earlier detection of infections 
and therefore a higher incidence rate. Indeed, among a study 
exploring HCV testing rates among 7 US sites between 2000 
and 2011, the UCSD Owen Clinic had one of highest HCV 
study entry screening rates and the second highest for HCV in-
cidence [29]. Additionally, the MACS and ACTG studies were 
from earlier time periods, when there was less awareness of 
the HCV epidemic, so it is possible that more recent estimates 
from those cohorts could show more frequent testing and 
higher incidence. Similarly, our result is higher than estimates 
from case notification data from New York, indicating HCV 
diagnosis rates among non-IDU HIV+ MSM of 0.6/100py, but 
the New York rates may underestimate true incidence as they 
are calculated from notified cases to the state [30] compared 
with our cohort study. Overall, HCV incidence rates reported 
among HIV+ MSM were lower than those reported among 
people who inject drugs (8%–25% per year) [31, 32].
Additionally, our study provides evidence suggestive of an 
increase in incidence in 2015 among HIV+ MSM in a US setting. 
Recent data from France indicate an increase in incidence from 
2012 to 2015 in HIV+ MSM [16], although there was a dramatic 
decline between 2014 and 2016 in the Netherlands [17]. Apart 
from 2015, we found no evidence of changing incidence in pre-
vious years from 2000–2014, similar to data from Boston [25], 
the MACS cohort (among participants in similar entry cohorts) 
[27], the HOPS cohort [26], and men in the ACTG cohort [28]. 
It is unclear whether the apparent increase in incidence in 2015 
will continue, or if it was a statistical anomaly. This elevation 
could potentially be due to increases in risk behavior, possibly 
associated with the availability of highly effective HCV direct-
acting antiviral therapies and/or HIV pre-exposure prophylaxis 
(PrEP) [33]. It is possible that the higher incidence observed 
in San Diego in 2015 is due to more frequent testing in 2015 
(possibly as a result of DAA availability), which could have 
contributed to an apparent increase in incidence in our study 
for this year. Enhanced vigilance is needed to monitor HCV in-
cidence and confirm whether the observed increase is sustained 
Table 2. Characteristics of HCV Reinfection Among HIV-Infected Men who Have Sex With Men who Attained SVR With HCV Treatment at Owen Clinic
All Individuals With SVR Individuals With HCV Reinfection Individuals Without HCV Reinfection
No. 43 3 40
Age, median (IQR), y 50 (42–54) 33 (32–51) 50 (43–55)
Follow-up duration, median (IQR), y 1.8 (1.1–3.5) 2.7 (2.5–5.9) 1.7 (0.9–3.4)
HCV genotype, No. (%):    
 –1 34 (79.0) 3 (100) 31 (77.5)
 –2 4 (9.3) 0 4 (10.0)
 –3 4 (9.3) 0 4 (10.0)
 –4 1 (2.3) 0 1 (2.5)
Abbreviations: HCV, hepatitis C virus; IQR, interquartile range; SVR, sustained viral response.
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and, if so, what prevention efforts are needed to control the 
epidemic.
Of note, we observed 3 HCV infections among 43 successfully 
treated HIV+ MSM. All of them were treated with interferon-
containing regimens. Our observed reinfection rate is possibly 
lower than the rates observed in other European studies, but 
the sample size is too small to draw meaningful conclusions. 
Retrospective studies in the United Kingdom [19] and the 
Netherlands [20] showed that HIV+ MSM who cleared HCV 
infection remain at high risk of reinfection, with an overall rate 
of 7.8/100py and 15.2/100py, respectively. More recently, a large 
retrospective analysis of reinfections in HIV+ MSM in 8 centers 
across Europe found a reinfection rate of 7.3/100py (95% CI, 
6.2–8.6) [34]. Additional studies from across the United States 
examining HCV reinfection, particularly in the DAA era, will 
allow for a more precise estimate of reinfection in this popula-
tion. Regardless, the observation of reinfection points toward 
the importance of frequent retesting post-treatment and the 
support needed to reduce reinfection risk.
Limitations
Our study was limited by several potential factors. First, as 
mentioned above, our incidence estimate could be biased by 
frequency and targeting of HCV testing. If individuals are in-
frequently tested, this could underestimate HCV incidence. 
However, individuals at our clinics had an average test interval 
of 1.1  years, indicating relatively frequent testing among the 
HIV+ MSM population but many who were tested less fre-
quently than the Centers for Disease Control and Prevention 
recommendations for annual testing. Alternatively, if higher-
risk (or lower-risk) individuals are tested, this could lead to 
an overestimation (or underestimation) of HCV incidence. 
However, within our study, we did not find evidence that 
individuals were selectively targeted for testing (testing interval 
was similar between groups). Additionally, our unpublished 
data indicate an HCV prevalence among newly HIV-diagnosed 
MSM of 1% in San Diego, which indicates that few HIV+ MSM 
are infected with HCV before their HIV diagnosis, and there-
fore that our study is not excluding a potential higher-risk co-
hort already infected.
Second, we lacked detailed data on sexual risk behaviors 
among MSM that could be associated with HCV acquisition. 
Various studies have found associations with fisting [13, 35–37], 
rectal trauma with bleeding [37], condomless receptive anal in-
tercourse [14, 35, 38], group sex [35, 38], and recreational use of 
a variety of drugs before or during sexual contact [36], but we 
did not have data on these behaviors.
Third, our estimate of HCV reinfection was limited by a 
very small sample size of patients assessed mostly before the 
interferon-free DAA era. It is possible that the risk of infection/
reinfection could decrease due to scale-up of curative treatment 
and fewer infections or that it could increase due to heightened 
risk associated with awareness of curative, short-duration, tol-
erable treatments.
Fourth, our primary incidence analysis relied on evidence of 
negative HCV antibody at entry and at least 1 more anti-HCV 
or RNA test, so we may have misclassified some individuals 
with absent or very delayed seroconversion. Two studies re-
port seroconversion among HIV+ MSM with acute infection. 
One UK study among 54 HIV+ MSM with acute infection 
reported that 5% had not seroconverted within 1  year [39]. 
Among a recent Dutch study of 63 HIV+ MSM with acute 
HCV infection, 98% had seroconverted within 1 year, and all 
seroconverted within follow-up [40]. As such, it appears that 
the vast majority, if not all individuals, achieve seroconversion, 
but a small proportion (<5%) may require longer than 1 year. It 
is difficult to predict how very delayed seroconversion would 
affect our results. In this case, for incident infections occurring 
during our study, we would have overestimated person-years at 
risk and therefore underestimated true incidence. On the other 
hand, incident infections that occurred before cohort entry but 
resulted in seroconversion during our study would have pos-
sibly underestimated true person-years at risk. If some HIV+ 
MSM never achieve seroconversion, we may have misclassified 
individuals at risk of infection at cohort entry (leading to over-
estimation of person-years at risk) and also failed to observe 
seroconversions during our study (leading to underestimation 
of incident infections), thus underestimating true incidence. 
Nevertheless, the impact of this relatively rare phenomenon is 
likely small and unlikely to change the broad trends observed.
Finally, our analysis was derived from 2 of the largest HIV 
clinics in San Diego, providing care for approximately one-
third of the estimated HIV+ MSM diagnosed in San Diego, 
with sociodemographic and HIV risk factor charactersitics that 
mirror the overall distribution of people living with HIV in San 
Diego County [22]. Therefore, we believe that it is generalizable 
to San Diego, but it is unclear whether the results of our study 
are applicable to the wider MSM community elsewhere and 
whether these trends will persist in the interferon-free DAA 
era. However, our population under care encompasses a high 
proportion of vulnerable people with ongoing barriers to care, 
similar to other large inner-city HIV populations burdened by a 
high prevalence of HCV coinfection [41]. Notably, although we 
noted demographic differences between the VA Hospital and 
the Owen Clinic, we observed a similar incidence of HCV in-
fection, suggesting that risk is likely similar between clinics.
CONCLUSIONS
HCV incidence was high and increased in 2015 among HIV+ 
MSM in San Diego. There is an urgent need for strong testing 
guidelines in this population and active prevention efforts, in-
cluding rapid diagnosis and HCV treatment, as well as behav-
ioral risk reduction strategies. Additionally, our work provides 
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the foundation for future analyses assessing what is required 
to achieve the WHO HCV elimination targets in this popula-
tion. Recent epidemic modeling has indicated that scaled-up 
HCV treatment among HIV+ MSM, particularly if combined 
with behavioral risk reduction, can substantially reduce HCV 
primary and reinfection incidence among HIV+ MSM in the 
United Kingdom [15] and Switzerland [42]. Tantalizing real-
world evidence from countries with universal health care sys-
tems such as the Netherlands indicating a halving in HCV 
incidence among HIV+ MSM over the 2-year period since 
widespread DAA expansion provides optimism that treatment 
scale-up could control the HCV epidemic among MSM [17]. 
Additional modeling is needed to assess optimal and cost-ef-
fective testing and treatment strategies in the MSM population 
in the United States and to determine what is required for HCV 
elimination.
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